COGT Stock Forecast & Price Target

Cogent Biosciences is supported by a compelling clinical and regulatory backdrop, with bezuclastinib showing strong activity in genetically defined KIT-driven disease and now carrying three NDA reviews, including PDUFA dates of November 30, 2026, December 30, 2026, and June 29, 2027. The APEX data in advanced systemic mastocytosis were particularly persuasive, with a 65% ORR, 81% response by pure pathological criteria, and 12-month PFS/OS of 79%/87%, reinforcing confidence in approval and broad commercial potential across multiple indications. Financially, the company ended 3Q26 with $791.1M in cash and equivalents, which should fund operations into late 2028 despite a 3Q26 net loss of $0.59 per share and elevated R&D and SG&A spending.

Cogent Biosciences is viewed negatively because AdvSM remains a highly competitive market, with Sanofi’s Ayvakit already established as the standard of care and physicians having meaningful experience with an effective KIT inhibitor. The company may need substantial commercial investment to gain meaningful utilization, which pressures future economics and raises the bar for adoption of CGT9486. Near-term downside risk is driven by potentially weaker-than-expected clinical data, which could reduce market penetration assumptions, lengthen approval timelines or even prevent approval, while competition and regulatory or commercial setbacks add further uncertainty.